Recent News

and/or

19 News Items found

In the Clinic

Longest-Running CAR T Trial Shows Which Patients Benefit Most, Have Fewest Side Effects

For adults with chemotherapy-resistant leukemia, CAR T cell therapy can be a lifesaving treatment option. New results suggest how to make it safer.

Medical oncologist Jae Park

In the News

Year in Review: The Science and Technology that Shaped Cancer Care in 2017

As 2017 draws to a close, take a look back at the scientific discoveries that deepened our understanding of cancer in the past year.

Gears with 2016 and 2017

In the Lab

Why Do Immune Checkpoint Inhibitors Work for Only Some People with Cancer?

Learn about why checkpoint inhibitors, a class of immunotherapy drugs, 
is paying off — but only for some patients.

MSK physician­scientist Luis Diaz

In the Clinic

Genetic ‘Scars’ Provide Clues for Tailoring Cancer Treatment

For the first time, scientists have determined the extent of DNA repair deficiencies across cancer types. Learn what it means for patients.

Image of DNA helix with sequence in the background

Finding

Making an IMPACT: MSK’s Gene-Sequencing Test Reveals New Findings about Hereditary Cancer Risk

An analysis of germline DNA in people with advanced cancer finds that inherited mutations may be more common than expected in this group.

Kenneth Offit and Vijai Joseph

Announcement

FDA Approves First CAR T Cell Therapy for Leukemia

Children, teens, and young adults with leukemia that have stopped responding to chemotherapy are the first eligible to receive the new treatment.

Pediatric oncologist Kevin Curran with CAR T patient Esmeralda Pineda

Announcement

FDA Approves Enasidenib (Idhifa), a First-of-Its-Kind Drug, for Advanced Blood Cancer

A new treatment option for people with acute myeloid leukemia is available, and it works in an unconventional way.

Acute myeloid leukemia cells under a microscope

In the Clinic

FDA Grants Breakthrough Therapy Designation to Omburtamab for Metastatic Neuroblastoma

A drug created at MSK called burtomab reaches an important milestone toward becoming a treatment for metastatic neuroblastoma.

MSK pediatric oncologist and neuroblastoma expert Kim Kramer

In the Clinic

The Science Behind the FDA’s Approval of an Immunotherapy for Mismatch Repair–Deficient Cancers

A new paper from MSK physician-scientist Luis Diaz presents the evidence on which the FDA approved the immunotherapy drug pembrolizumab for cancers with a specific genetic abnormality.

MSK medical oncologist Luis Diaz, Jr.

In the News

#ASCO17: Post-Conference Roundup of Themes and Trends

Read up on the progress being made in several key areas of cancer research, including immunotherapy, targeted therapy, precision surgery, and epigenetics.

American Society of Clinical Oncology logo